The estimated Net Worth of Nicki Vasquez is at least $120 millier dollars as of 29 January 2024. Dr Vasquez owns over 12,185 units of Sutro Biopharma Inc stock worth over $59,022 and over the last 3 years he sold STRO stock worth over $60,925.
Dr has made over 8 trades of the Sutro Biopharma Inc stock since 2021, according to the Form 4 filled with the SEC. Most recently he sold 12,185 units of STRO stock worth $60,925 on 29 January 2024.
The largest trade he's ever made was exercising 12,250 units of Sutro Biopharma Inc stock on 3 March 2023 worth over $56,473. On average, Dr trades about 5,926 units every 107 days since 2021. As of 29 January 2024 he still owns at least 12,803 units of Sutro Biopharma Inc stock.
You can see the complete history of Dr Vasquez stock trades at the bottom of the page.
Dr. Nicki Vasquez Ph.D. is the Chief Portfolio Strategy & Alliance Officer at Sutro Biopharma Inc.
Nicki's mailing address filed with the SEC is C/O SUTRO BIOPHARMA, INC., 111 OYSTER POINT BLVD., SOUTH SAN FRANCISCO, CA, 94080.
Over the last 6 years, insiders at Sutro Biopharma Inc have traded over $14,451,171 worth of Sutro Biopharma Inc stock and bought 750,858 units worth $10,652,478 . The most active insiders traders include Corp /De/ Celgene, John Gordon Freund et Daniel Janney. On average, Sutro Biopharma Inc executives and independent directors trade stock every 19 days with the average trade being worth of $129,762. The most recent stock trade was executed by Jane Chung on 9 August 2024, trading 18,750 units of STRO stock currently worth $86,438.
at sutro biopharma we have pioneered a compelling and unique way of discovering, developing and manufacturing therapeutics. our focus is aimed primarily on next generation cancer therapeutics — antibody conjugates and bispecific antibodies. unconstrained by traditional methods of cell-based discovery, we can design and develop targeted medicines by innovating outside the constraints of the cell. our technology enables us to iteratively discover and test molecules in a rapid cycle of weeks rather than months, to rapidly identify the optimal molecule designed for safety and potency. our approach to discovery, without the cell, is also transcending the the limitations of biologics manufacturing. sutro has the world’s only cgmp cell-free manufacturing facility located in san carlos, california. this state-of- the-art facility confers an important competitive advantage as we head into human clinical trials in 2018. in addition to developing our own oncology pipeline, sutro biopharma is coll
Sutro Biopharma Inc executives and other stock owners filed with the SEC include: